Patients with a rare bone cancer of the skull and spine — chordoma — could be helped by existing drugs, suggest scientists. In the largest genomics study of chordoma to date, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors.